Result of AGM
Proteome Sciences plc announced that all resolutions were passed at its Annual General Meeting, with strong support for the Directors' Report and audited financial statements for the year ended 31 December 2025, receiving 147,914,675 votes for and only 2,800,402 against. Similarly, the Remuneration Report was approved with 146,482,388 votes for. The re-appointment of all directors, including Christopher Pearce, Richard Dennis, Ian Pike, Ursula Ney, and Martin Diggle, also saw overwhelming approval, with votes for ranging from 147,564,238 to 147,741,085. The re-appointment of auditors Cooper Parry Group Limited and the authorisation for directors to allot equity securities up to £1,168,966.13 and dis-apply pre-emption rights up to £701,449.82 were also passed with significant majority support.
Select text to share a quote on X · sign in to keep highlights & notes in your PRM notes
The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 12.00 noon today, all resolutions were duly passed.
For information, the proxy votes received in relation to the resolutions were as follows:
| RESOLUTION MATTER | VOTES FOR | VOTES AGAINST | VOTES DISCRETIONARY | VOTES WITHHELD | VOTES TOTAL |
|---|---|---|---|---|---|
| 1. To receive the report of the Directors and the audited Financial Statements of the Company for the year ended 31 December 2025. | 147,914,675 | 2,800,402 | 539 | 71,282 | 150,786,898 |
| 2. To receive and approve the Remuneration Report, excluding the remuneration policy. | 146,482,388 | 4,232,689 | 539 | 71,282 | 150,786,898 |
| 3. To re-appoint Christopher Pearce as a Director of the Company. | 147,740,986 | 2,890,589 | 0 | 155,323 | 150,786,898 |
| 4. To re-appoint Richard Dennis as a Director of the Company. | 147,704,238 | 2,947,337 | 0 | 135,323 | 150,786,898 |
| 5. To re-appoint Ian Pike as a Director of the Company. | 147,724,238 | 2,927,337 | 0 | 135,323 | 150,786,898 |
| 6. To re-appoint Ursula Ney as a Director of the Company. | 147,741,085 | 2,910,490 | 0 | 135,323 | 150,786,898 |
| 7. To re-appoint Martin Diggle as a Director of the Company. | 147,564,238 | 3,067,337 | 0 | 155,323 | 150,786,898 |
| 8. To re-appoint Cooper Parry Group Limited as auditors of the Company and to authorise the Directors to determine the remuneration of the auditors. | 147,796,267 | 2,890,439 | 0 | 100,192 | 150,786,898 |
| 9. To authorise the Directors to exercise all or any of the powers of the Company to allot equity securities up to an aggregate nominal amount of £1,168,966.13. | 147,727,873 | 2,978,396 | 0 | 80,629 | 150,786,898 |
| 10. To empower the Directors to dis-apply statutory pre-emption rights up to a maximum aggregate nominal amount of £701,449.82. | 146,526,989 | 4,179,957 | 0 | 79,952 | 150,786,898 |
| Proteome Sciences plc | |||||
| Christopher Pearce, Executive Chairman | Tel: +44 (0) 20 7043 2116 | ||||
| Dr. Ian Pike, Chief Scientific Officer | |||||
| Richard Dennis, Chief Commercial Officer | |||||
| SP Angel Corporate Finance LLP (Nominated Adviser & Broker) | |||||
| David Hignell/Richard Morrison/Josh Ray (Corporate Finance) Vadim Alexandre (Corporate Broking) | Tel: +44 (0) 20 3470 0470 | ||||
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.